sub:assertion {
  d:DB01076 dv:ddi-interactor-in dr:DB01076_DB08827 .
  d:DB08827 dv:ddi-interactor-in dr:DB01076_DB08827 .
  dr:DB01076_DB08827 dct:identifier "drugbank_resource:DB01076_DB08827" ;
    dct:title "DDI between Atorvastatin and Lomitapide - Atorvastatin, and other weak CYP3A4 inhibitors (such as amiodarone, amlodipine, alprazolam, bicalutamide, cilostazol, cimetidine, cyclosporine, fluoxetine, fluvoxamine, ginko, goldenseal, isoniazide, lapatinib, nilotinib, oral contraceptives, pazopanib, ranitidine, ranolazine, tipranavir/ritonavir, ticagrelor, zileuton) increase lomitapide levels by 2-fold. Thus lomipatide should be dosed at a maximum of 30mg daily when used concomitantly with weak inhibitors of CYP3A4."@en ;
    a dv:Drug-Drug-Interaction ;
    rdfs:label "DDI between Atorvastatin and Lomitapide - Atorvastatin, and other weak CYP3A4 inhibitors (such as amiodarone, amlodipine, alprazolam, bicalutamide, cilostazol, cimetidine, cyclosporine, fluoxetine, fluvoxamine, ginko, goldenseal, isoniazide, lapatinib, nilotinib, oral contraceptives, pazopanib, ranitidine, ranolazine, tipranavir/ritonavir, ticagrelor, zileuton) increase lomitapide levels by 2-fold. Thus lomipatide should be dosed at a maximum of 30mg daily when used concomitantly with weak inhibitors of CYP3A4. [drugbank_resource:DB01076_DB08827]"@en .
}